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Abstract Reactivation of viral infections is common in pa-
tients with solid tumour or haematological malignancy. Inci-
dence and severity depend on the extent of cellular immuno-
suppression. Antiviral prophylaxis may be effective to prevent
viral reactivation. In 2006, the Infectious Diseases Working
Party of German Society for Hematology and Medical Oncol-
ogy (DGHO) published guidelines for antiviral prophylaxis in
these patient populations. Here, we present an update of these
guidelines for patients with solid and haematological malig-
nancies undergoing antineoplastic treatment but not
allogeneic stem cell transplantation. Relevant literature for
reactivation of different viruses (herpes simplex virus
(HSV), varicella zoster virus (VZV), hepatitis B virus
(HBV) and respiratory viruses) is discussed to provide
evidence-based recommendations for clinicians taking care
of this patient population. We recommend a risk-adapted ap-
proach with (val)acyclovir against HSV and VZV in patients
treated with alemtuzumab, bortezomib or purine analogues.
Seasonal vaccination against influenza is recommended for
all patients with solid or haematological malignancies regard-
less of antineoplastic therapy. Hepatitis B screening is recom-
mended in lymphoproliferative disorders, acute leukaemia,
and breast cancer, and during treatment with monoclonal
anti-B-cell antibodies, anthracyclines, steroids and in autolo-
gous stem cell transplantation. In those with a history of hep-
atitis B prophylactic lamivudine, entecavir or nucleotide ana-
logues as adefovir are recommended to prevent reactivation.
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Introduction
The risk of patients with solid tumours or haematological ma-
lignancies to contract viral infections is relatively low. Viral
diseases occur most likely as reactivation of latent infections
with herpes simplex virus (HSV), varicella zoster virus (VZV)
and hepatitis B virus (HBV) being the most common viruses
in these patients [1]. Apart from the setting of allogeneic stem
cell transplantation, cytomegalovirus (CMV) and Epstein-
Barr virus (EBV) play a subordinate role.
In recent years, the clinical relevance of viral infections of
the respiratory tract has been increasingly recognized. Most
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viral infections are exogenous, primary infections. Influenza
viruses are particularly important since patients with malig-
nancies have an increased risk of contracting infections [2].
Moreover, an increased rate of secondary complications in-
cluding bacterial pneumonia and fatal outcome has been ob-
served [3].
The major risk factor for the occurrence of viral complica-
tions is the extent of cellular immunosuppression. The risk
increases with the intensity and duration of T-cell suppression,
as seen in the rate of viral complications during treatment with
the T-cell antibody alemtuzumab. Severity and duration of
neutropenia are of minor importance.
In 2006, the Infectious Diseases Working Party (AGIHO)
of the German Society for Hematology and Medical Oncolo-
gy (DGHO) published guidelines on antiviral prophylaxis in
this patient population including recipients of allogeneic stem
cell transplants [4]. The present aim of this guideline is to
update the recommendations for patients with solid tumours
and haematological malignancies. Recommendations for re-
cipients of allogeneic stem cell transplants will be published
separately and are not discussed here.
These guidelines have been prepared and composed by an
expert panel from the AGIHO. Relevant literature published
after 2006 was identified and reviewed using MEDLINE,
CANCERLIT and the Cochrane library. Recent study results
presented at major meetings in this field, including ASH,
EHA, ASCO, ESMO, ECCMID or ICAAC, were additionally
taken into account. The results were further discussed and
finally approved by the assembly of the members of the
AGIHO. The present article summarizes the development
and rationale of the recommendations.
The aim of these guidelines is to provide physicians with
evidence-based recommendations for the prevention of viral
reactivations and primary viral infections in patients with solid
tumours and haematological malignancies. In contrast to other
published guidelines [5, 6], its relevance for a day-by-day use
in the clinical setting is based on the evidence of recommen-
dations as proposed by the Infectious Disease Society of
America (IDSA) (see Table 1) [7]. The risk of viral complica-
tions and respective preventive strategies were determined
depending on the underlying disease and specific therapies,
i.e. chemotherapy with or without administration of monoclo-
nal antibodies.
Patient populations
Conventionally dosed chemotherapy in solid tumours
and haematological malignancies
Patients treated with conventionally dosed chemotherapy
for their malignancy are at low risk for clinically relevant
v i r u s r e a c t i v a t i o n s . T h e d e g r e e o f c e l l u l a r
immunosuppression in patients with solid tumours is very
limited. Furthermore, the majority of chemotherapeutics
does not lead to a substantial suppression of T-cell func-
tion. Thus, the reactivation of HSV, VZV [8], EBV or
CMV (30) constitutes a rare event in this patient popula-
tion and does not require prophylaxis.
In contrast, the risk of primary viral infections of the upper
respiratory tract is notably increased in patients with an active
malignancy, with infections due to influenza, parainfluenza
and respiratory syncytial virus (RSV) being the most clinically
relevant [9–11]. As there are no effective prophylactic drugs,
the instruction and performance of general hygiene measures
represent an important prophylactic action [12, 13]. Despite
the high variability in the response to the attenuated influenza
vaccine in these patients [14], the influenza vaccine is recom-
mended in patients with an active malignancy undergoing
chemotherapy [15].
Induction and consolidation therapy in acute leukaemia
patients results in a high risk for infectious complications.
The occurrence of severe and persistent neutropenia with neu-
trophil counts below 500/μl or even 100/μl leads to an in-
creased risk for febrile complications, mostly due to bacterial
or fungal infections. Most viral infections during neutropenia
are due to HSV [16]. A severe mucositis can impair the mu-
cosal barrier leading to an increased risk for bacterial infec-
tions. Thus, the continuation of curative chemotherapy can be
delayed. In addition, mucositis due to viruses results in signif-
icant deterioration of the patient’s general condition by caus-
ing severe pain, reduction of nutritional intake and cachexia.
These complications are good reasons to prevent HSV reacti-
vation. However, several studies could not prove a significant
effect of acyclovir prophylaxis on the time and duration of
antibiotic treatment, the number of febrile days, the rate of
bloodstream infections and other opportunistic infections or
mortality [17–19]. Accordingly, there is not enough evidence
from randomized trials on antiviral prophylaxis for HSV in
patients with acute leukaemia to establish a strong recommen-
dation [20]. In contrast, the vaccination for influenza is rec-
ommended for all patients with acute leukaemia after inten-
sive chemotherapy and for acute lymphoblastic leukaemia
during the course of maintenance treatment [21].
Reactivation of hepatitis B virus infection is rather com-
mon in patients with solid tumours and haematological malig-
nancies undergoing conventional chemotherapy and consti-
tutes a serious complication for those patients [22–25]. In
hepatitis B surface antigen (HBsAg) positive patients, the rate
of reactivation is approximately 20–50 %, resulting in fulmi-
nant hepatitis and a high lethality in some cases. The risk is
especially high in patients with malignant lymphoma and
those undergoing treatment with anthracyclines [26, 27] or
higher doses of steroids (10–20 mg prednisone daily or equiv-
alent ≥4 weeks) [28, 29]. Primary antiviral prophylaxis with
nucleoside analogues lamivudine and entecavir as well as
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nucleotide analogues adefovir and tenofovir are effective in
the prevention of reactivation in patients with evidence of
previous hepatitis B infection. Prophylaxis was associated
with an 87 % relative risk reduction of reactivation [30] and
also prevents fulminant hepatitis effectively [31]. Successful
prophylaxis is of high prognostic value in patients with a
curable underlying disease; patients can continue chemother-
apy in time without interruption or dose reduction due to
hepatitis.
Mono- and combination therapies with purine analogues
like fludarabine or pentostatin result in a sustainable cellular
immunosuppression and an increased risk for opportunistic
infections [32, 33]. In the setting of first-line treatment,
reactivations of VZVand HSVare rarely observed. Thus, pri-
mary prophylaxis with acyclovir cannot be recommended in
this patient population.
In the presence of clinical risk factors including CD4+ cell
count <50/μl, long-term treatment with steroids, persistent
neutropenia, age more than 65 years or an advanced stage of
underlying disease, antiviral prophylaxis can be reasonable
[34]. Results from newer studies since 2006 do not substan-
tially change the recommendations regarding risk and prophy-
lactic strategy with acyclovir or valacyclovir to prevent VZV
or HSV reactivation.
In conclusion, no general recommendation regarding pro-
phylactic medication for HSV, EBVor CMV in patients with
solid tumours and haematological malignancies undergoing
conventionally dosed chemotherapy can be given (see Ta-
ble 2). The risk of viral reactivation is low due to only limited
cellular immunosuppression, and evidence from randomized
trials is missing. This is different for influenza and HBV; for
these viruses, evidence-based strategies to prevent primary
infection (influenza) or reactivation of latent infection
(HBV) exist (see Table 2 and Fig. 1).
Monoclonal antibodies
Administration of monoclonal antibodies has become an inte-
gral part of treating malignancies. In the treatment of solid
tumours, antibodies against growth factors of angiogenesis
and against growth receptors like the EGF-receptor are well
established. Examples include the combination of
trastuzumab, bevacizumab or cetuximab with classical che-
motherapy in the treatment of breast and colorectal cancer.
In lymphoproliferative diseases, targeted therapy against
CD20 and—more recently—CD30 is widespread. The admin-
istration of rituximab, an anti-CD20 antibody, represents the
basis of the treatment of B-cell lymphoma [35, 36]. Second
generation antibodies like ofatumumab or obinutuzumab are
about to be integrated in everyday clinical practice.
This treatment leads to a sustained B-cell depletion and,
thus, increases the risk of viral reactivations. Most clinically
relevant in this setting is the reactivation of HBV, which can
occur in up to 50 % of patients with previous hepatitis B
[37–40]. Reactivations of HSV, VZV, CMV, EBV and other
viruses are more infrequent. The substantial cellular immuno-
suppression caused by the anti-CD20 therapy is also evident
i n a s soc i a t ed ca s e s o f p rog r e s s i v e mu l t i f o c a l
leukencephalopathy as a result of JC virus reactivation [41].
On the basis of current evidence, there is no rationale for
prophylaxis against HSV, VZV, EBV or CMV during B-cell
antibody treatment. Nevertheless, particular attention should
be paid to clinical signs of viral reactivation, as a wide variety
of atypical pathogens can cause severe infections during the
course of treatment. To prevent influenza infection, vaccina-
tion is recommended. Despite the predominantly inadequate
immune response under treatment with B-cell antibodies,
some results indicate reduced severity of influenza infections
after vaccination [42, 43].
Table 1 Infectious Diseases
Society of America—United
States Public Health Service




A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation
D Moderate evidence to support a recommendation against use
E Good evidence to support a recommendation against use
Quality of evidence
I Evidence from ≥1 properly randomized, controlled trial
II Evidence from ≥1 well-designed clinical trial, without randomisation;
from cohort or case-controlled analytic studies (preferably from >1 centre);
from multiple time-series; or from dramatic results from uncontrolled
experiments
III Evidence from opinions of respected authorities, based on clinical experience,
descriptive studies, or reports of expert committees
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Additionally, all patients receiving B-cell antibodies should
be screened for chronic hepatitis B as a clinical standard [44].
This recommendation has been expressed in guidelines of
different societies [45–52]. The cost-effectiveness of this strat-
egy has recently been demonstrated in patients receiving R-
CHOP (rituximab plus cyclophosphamide, doxorubicin, vin-
cristine and prednisone) for malignant lymphoma [53].
The algorithm of screening and antiviral prophylaxis for
hepatitis B is explained in the chapter on antiviral substances
and in Fig. 1.
The administration of anti-CD30 antibodies linked with a
cytostatic (i.e. brentuximab vedotin) is an established alterna-
tive in the therapy of relapsed Hodgkin’s lymphoma and in
CD30-positive anaplastic large-cell lymphoma [54]. There are
reports of an increased incidence of opportunistic infections;
viral reactivations, however, are not a major concern. On the
basis of already existing data, no general recommendation on
antiviral prophylaxis can be made.
Currently, alemtuzumab, an anti-CD52 antibody, is only
rarely used for treatment of CLL. Several studies have shown
that the incidence of reactivations of HSV, VZVand CMV is
considerably high [55]. Therefore, prophylaxis with acyclovir
for HSVand VZVas well as monitoring of CMV reactivation
by PCR or detection of the early antigen in peripheral blood
has become standard. No changes apply to the recommenda-
tions of 2006 [4].
Proteasome inhibitors
Bortezomib is a proteasome inhibitor and a standard treatment
for multiple myeloma. The substance is usually given in com-
bination with dexamethasone or with classical cytostatics. It
can be used both in primary therapy and for relapsed disease.
Another molecule of this class is carfilzomib, a second-
generation proteasome inhibitor, which has recently been ap-
proved by the Food and Drug Administration (FDA) [56].
The APEX study showed an increased VZV reactivation
rate in patients receiving bortezomib [57]. These reactivations
can be effectively prevented by low-dose acyclovir prophy-
laxis, as reported in several phase II trials and retrospective
analyses [58–61]. However, to date, there are no randomized
phase III trials addressing this question. On the basis of the
given results, a recommendation for VZV prophylaxis by low-
dose acyclovir or valacyclovir can be made. Further prophy-
lactic agents are not indicated in this setting.
Table 2 Evidence-based recommendations for antiviral prophylaxis in patients with solid tumours and haematological malignancies except hepatitis B
Chemotherapy Rituximab Alemtuzumab Proteasome inhibitors Purine analogues Autologous SCT
HSV/VZV None (CII) None (CII) Acyclovir (AII) Acyclovir (AII) Acyclovira (AII) None (CII)
Influenza Vaccination (AII) Vaccination (BIII) Vaccination (BIII) Vaccination (AIII) Vaccination (BIII) Vaccination (BIII)
CMV None (CII) None (CII) None (BII) None (CIII) None (CIII) None (CII)
EBV None (EIII) None (EIII) None (EIII) None (EIII) None (EIII) None (EIII)
Resp. viruses adenovirus None (CII) None (CII) None (CII) None (CII) None (CII) None (CII)
HCV None (CII) None (CII) None (CII) None (CII) None (CII) None (CII)
a In the presence of risk factors: second-line therapy, prolonged treatment with steroids, CD4 count <50/μl, age >65 years, neutrophil count <1000/μ
ALL, AML, malignant lymphoma, CLL, mulple myeloma, breast cancer, or treatment with
anthracyclines, high-dose steroids, an-CD20, alemtuzumab, purine analogues
Screening: HBs-Ag and an-Hbc
HBs-Ag HBs-Ag , an-HBc HBs-Ag , an-HBc
HBV-DNA 
< 2000 IU/ml
therapy < 12 mo.
HBV-DNA
> 2000 IU/ml




No prophylaxis HBV-DNA HBV-DNA 
Monitor HBV DNA
Fig. 1 Algorithm for prophylaxis
of HBV reactivation
1444 Ann Hematol (2015) 94:1441–1450
Patients with multiple myeloma present with marked im-
mune deficiency that—as compared to other lymphoprolifer-
ative diseases—can be accompanied by a distinct antibody
deficiency syndrome. Therefore, immunization is an impor-
tant measure in preventing infections in this patient population
[56]. Seasonal influenza vaccination is indicated for patients
with multiple myeloma both with or without treatment with
proteasome inhibitors [62].
Autologous stem cell transplantation
The risk of opportunistic infections after autologous stem cell
transplantation (SCT) correlates with the immune reconstitu-
tion. As T-cell depleted grafts are no longer used, the cellular
immune deficiency is usually mild. However, it correlates
with the extent of pre-treatment and the remission state of
the underlying disease. Pre-treatment with high dose steroids
or a transplantation after the second or higher relapse lead to
marked cellular immunosuppression and thus to an increased
risk for viral reactivations. Antiviral prophylaxis may thus be
helpful in individual cases.
Reactivations of HSV and VZV leading to mucocuta-
neous infections are paramount after autologous SCT
[63]. HSV infections may occur along with mucositis after
high dose chemotherapy until the regeneration of the
granulocytes. VZV reactivation is more frequent after re-
constitution of granulopoesis until day 100 after trans-
plantation. Reported incidences differ and vary from 8 to
20 % [64].
No new evidence-based data addressing this topic has been
generated since 2006. In particular, no randomized trials on
antiviral prophylaxis have been conducted. As a result, the
recommendations of this guideline regarding antiviral prophy-
laxis after autologous SCT do not differ from those published
previously [4]. General administration of acyclovir or
valacyclovir for the prophylaxis of HSVor VZV reactivation
is not recommended [20]. Such prophylaxis may depend on
an individualized risk assessment per patient. Relevant factors
for this include the extent of pre-treatment, the remission state
at the time of transplantation, comorbidities, age, previous
infections during the course of the disease and CD4+ count.
However, no controlled randomized studies have been con-
ducted to evaluate the efficacy of such an individualized
approach.
The risk of CMVreactivation after autologous SCTwithout
T-cell depletion is very low [65]. There is no rationale for
prophylaxis.
Analogous to previously described clinical scenarios, there
is an indication for HBV prophylaxis in patients with chronic
hepatitis B. No changes were applied to the recommendations
of 2006—including the recommendation for the seasonal in-
fluenza vaccination [21, 66].
Small molecules and signal transduction inhibitors
The principle of signal transduction inhibition is an inherent
part of modern tumour therapy today. Examples include
mTOR inhibitors (e.g. everolimus) or interferences in the sig-
nal transduction of EGFR- or JAK2-pathways. A promising
approach is seen in molecules, which interfere in the signal
transduction of B-cell receptors (e.g. ibrutinib) and therefore
present an attractive therapeutic option for B-CLL and B-cell
lymphoma [67, 68]. Humoral as well as cellular immunosup-
pressionmay be common in patients treated with these agents,
especially in those who are heavily pretreated. Therefore, an-
tiviral prophylaxis may be indicated on an individual risk
basis.
There are a growing number of reports on increased rates of
opportunistic infections under this treatment [69]. However, in
the COMFORT II trial, which compared the efficacy of
ruxolitinib with the best available treatment in patients with
myelfibrosis, the incidence of infections decreased over time
without focus on reactivation of viral infections [70]. Wang
et al. report similar results for a long-term follow-up of treat-
ment with ibrutinib in patients with mantle-cell lymphoma
[71]. Regarding reactivation of HBV, prophylaxis with
lamivudine is an effective strategy to prevent reactivation
[72].
An evidence-based recommendation for antiviral prophy-
laxis, thus, cannot be generated.
Prophylactic treatment
Herpes simplex virus and varicella zoster virus
The unaltered standard in the prophylaxis of HSV and
VZV is acyclovir 400 mg tid or qid or valacyclovir
500 mg bid or tid [73]. Superiority of one of the two
drugs could not yet be demonstrated [74, 75]. Treatment
should be initiated during the first week of antineoplastic
therapy and continued beyond the end of therapy. So far,
the best duration of prophylaxis could not be determined.
We recommend monitoring CD4+ T-cell levels and the
continuation of antiviral prophylaxis until the count is
above 200/μl. However, there are no randomized trials
for this strategy.
Regarding prophylaxis of VZV during therapy with
proteasome inhibitors, a lower dose of acyclovir or
valacyclovir has shown to be effective. Dosages as low
as 200–400 mg for acyclovir or 500 mg for valacyclovir
daily or bid were successfully used [54–57]. Randomized
trials comparing the different dosages, however, do not
exist, and the risk of acyclovir resistance by using low
doses has not been assessed yet.
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Influenza viruses
Seasonal vaccination against influenza can be recommended
for all patients with solid tumours or haematological malig-
nancies regardless of antineoplastic therapy [13, 21, 62, 76,
77]. Despite reduced immunological competence, there is ev-
idence showing that 70–80 % of patients with malignancies
exhibit seroconversion after a vaccination [78, 79].
Patients with malignant lymphoma or multiple myeloma
show a reduced response in comparison to patients with solid
tumours [80]. Hence, a second vaccination can be reasonable
in this patient population. According to the results of the
VACANCE trial, the rate of seroconversion in patients with
solid tumours was increased from 44 to 73 % after a second
administration of influenza vaccine [81]. Yet the optimal
timing of a second vaccination—especially during ongoing
tumour therapy—is unclear. Some results suggest a better ef-
fectiveness when administering the vaccination directly after
chemotherapy instead of shortly before the next cycle [14].
In addition, vaccination of healthcare workers as well as
family and household members is of particular importance to
reduce influenza virus circulation and the risk of infection.
Hepatitis B virus
The risk of HBV reactivation during chemo- or immunother-
apy is sufficiently documented in the literature [82]. HBV
reactivation is of clinical relevance due to the high associated
morbidity and lethality [83]. Reactivations have been de-
scribed in all patients with a history of hepatitis B (that is,
anti-HBc positive) regardless of the serological constellation
(presence or absence of HB-antigens or anti-HBs) [84].
The incidence of reactivation varies in different patient
populations [24]. In patients with solid tumours, the reactiva-
tion rate of HBV was reported to be below 1 % [85]. Admin-
istration of anthracyclines is a negative prognostic factor in
these patients [26, 27]. On the other hand, HBV reactivation
occurs in 30–50% of patients with malignant lymphoma [86],
with even higher rates during treatment with rituximab [40,
44]
In conclusion, the following clinical risk factors are asso-
ciated with an increased risk of HBV reactivation:
– Treatment with anthracyclines
– Treatment with steroids: >10–20 mg prednisone daily or
equivalent for ≥4 weeks
– Treatment with monoclonal antibodies (rituximab,
obinutuzumab, ofatumomab, alemtuzumab)
– Breast cancer as underlying disease
– Malignant lymphoma as underlying disease
Preemptive treatment with lamivudine, entecavir or nucle-
otide analogues as adefovir is standard in the prophylaxis of
HBV reactivation [4, 45, 87]. This preemptive measure, how-
ever, requires the evidence of a previous infection. Therefore,
patients with haematological malignancies or patients with
solid tumours before planned tumour therapy should undergo
a screening on HBV infection. To date, it remains unclear
whether a general screening of all patients is needed.
We favour a risk-adapted approach and recommend HBV
screening in patients with malignant lymphoma, multiple my-
eloma, CLL, AML, ALL and breast cancer, as well as patients
planned for therapy with monoclonal B-cell antibodies,
alemtuzumab, chemotherapy protocols based on the use of
anthracyclines, higher doses of steroids and those undergoing
autologous SCT (AII). In this patient population, tests for
HBs-Ag and anti-HBc antibodies should be performed.
In case of HBsAg negativity and anti-HBc antibody nega-
tivity, antiviral prophylaxis is not indicated and immunisation
should be considered. Patients with a negative HBsAg and a
positive anti-HBc antibody test should be tested for HBV
DNA. Those with a positive viral load should receive prophy-
laxis while those with a negative PCR should be screened for
reactivation on a regular basis [45] (AIII). So far, the optimal
approach in this risk group is not defined. Depending on the
intensity of immunosuppression, monitoring should be repeat-
ed every 1–3 months. In patients who receive treatment with a
particularly high risk of HBV reactivation (e.g. anti-CD20
targeted therapy), antiviral prophylaxis regardless of HBV-
load should be considered.
In case of HBsAg positivity, the quantification of HBV
DNA may determine the agent for antiviral prophylaxis
(AI). Prophylactic treatment should be started together with
the immunosuppressive therapy. While there are not random-
ized trials investigating the optimal duration of prophylaxis,
reactivations have been described after the end of antineoplas-
tic therapy. Thus, antiviral prophylaxis should be continued
for 6–12months after the completion of antineoplastic therapy
(AII). The question of the most suitable antiviral drug for pro-
phylaxis in this patient population is still unanswered. Most
data on effectiveness exists for lamivudine. However, there
are a few randomized trials with newer substances such as
entecavir, adefovir or tenofovir [88]. Arguments for the latter
include a higher antiviral potency and a lower risk of resis-
tance development, which otherwise is substantially increas-
ing after 12 months of treatment with lamivudine.
We suggest a risk-adapted approach in accordance with
other recently published guidelines [30] (AIII). Prophylaxis
with lamivudine is appropriate in short-term cancer treatment
of approximately 4–6 months duration or in patients with a
viral load below 2000 IU/ml, which is associated with a low
risk of disease (42). In sustained immunosuppression for more
than 12 months, i.e. in rituximab maintenance therapy, or in
case of a high viral load above 2000 IU/ml, we recommend
applying substances with a higher antiviral potency like
entecavir or tenofovir (42) (see Fig. 1).
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Cytomegalovirus
In the above-described patient populations, there is no
evidence for CMV prophylaxis. Serological monitoring
of CMV reactivation by testing for early antigen or using
PCR in peripheral blood is obligatory during treatment
with alemtuzumab. It can be indicated in certain constel-
lations with increased risk in patients undergoing autolo-
gous SCT. In principle, PCR is to be preferred due to its
higher reliability not depending on the neutrophil count.
Epstein-Barr virus
Reactivation of EBV is rare in this patient population. Prophy-
laxis is not recommended.
Respiratory viruses—other than influenza virus
and adenovirus
Patients with solid tumours or haematological malignan-
cies have an increased risk for infections of the upper
respiratory tract regardless of their tumour therapy. Usu-
ally these are primary infections. Therefore, patients
should be monitored closely for clinical signs of infec-
tion. There is no indication for antiviral prophylaxis.
However, patients with evidence of infection with respi-
ratory viruses should be isolated to protect other pa-
tients from contracting the disease.
Hepatitis C virus
Hepatitis C (HCV) infection does not constitute a contraindi-
cation for therapy in these patients including those undergoing
autologous SCT. Standard cancer treatment in HCV positive
patients yields similar disease-free survival and overall surviv-
al rates compared to those who are HCV negative [89]. How-
ever, we recommend consultation of a hepatologist while set-
ting up the cancer treatment strategy. First, HCV infection is
associated with increased hepatic toxicity during chemothera-
py, and second, it might be appropriate to treat the viral infec-
tion simultaneously since the availability of interferon-free
anti-HCV therapy [90]. But in conclusion, at this moment,
no reasonable evidence-based preventive measure exists.
Conclusions
Patients with solid tumours and haematological malignancies
have—to different degrees—an increased risk for reactivation
or primary acquisition of viral infections. The risk correlates
with the intensity of cellular immunosuppression and, thus,
with the type of therapy. Depending on this risk, evidence-
based prophylaxis is indicated. This applies in particular to
HBV reactivation, herpes zoster and primary infections with
influenza virus.
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